In support of this theory, silencing of IGF2BP2/3, FTO, and METTL3 with specific inhibitors has been shown to suppress proliferation and reverse radio- and chemoresistance in multiple tumor types, including lung, cervical and pancreatic cancer, and glioma) [217, 218, 220, 275, 285], with ultimate improvement of treatment outcomes. The gene discussed is IGF2BP2; the disease is glioma.